Bogdanovski K., et al. (2018). High-dose Nitric Oxide inhibits growth of Mycobacterium Abscessus. ESCMID/ASM Conference on Drug Development to Meet the Challenge of Antimicrobial Resistance, Lisbon, Portugal, Sept 4-7 (available in print only)

Tal, A., et al. (2018). Nitric oxide inhalations in bronchiolitis: A pilot, randomized, double-blinded, controlled trial. Pediatr Pulmonol 53(1): 95-102.

Bogdanovski K., et al. (2018). High-Dose Inhaled Nitric Oxide as a Potential Therapy Against Mycobacterium Abscessus Lung Infection in Cystic Fibrosis. 3rd World Bronchiectasis Conference, Chronic Obstr Pulm Dis. 2018; 5(4): 302-323.

Olivier K.N., et al. (2018). Treatment of refractory mycobacterium abscessus lung infection with inhaled intermittent nitric oxide. 3rd World Bronchiectasis Conference, Chronic Obstr Pulm Dis. 2018; 5(4): 302-323.

Ghaffari, A. et al. (2018). High-dose nitric oxide as a potential new therapeutic agent against Mycobacterium abscessus. European Respiratory Journal 52: Suppl. 62, PA5463.

Goldbart, A., et al. (2018). A phase-III multicenter, randomized, double-blind, controlled trial of high-dose inhaled nitric oxide in infants with acute bronchiolitis. European Respiratory Journal 52: PA4642.

Bogdanovski K., et al. (2018). High-dose inhaled nitric oxide as a potential therapy against mycobacterium abscessus lung infection in cystic fibrosis. Pediatric Pulmonology, 52(S2): S1-S481

Yaacoby-Bianu, K., et al. (2018). Compassionate Nitric Oxide Adjuvant Treatment of Persistent Mycobacterium Infection in Cystic Fibrosis Patients. Pediatr Infect Dis J. 2018; 37(4):336-338.

Miller CC. et al., (2012). A phase I clinical study of inhaled nitric oxide in healthy adults. Journal of Cystic Fibrosis, 11:324-331

Miller CC, et al. (2007). Innate protection of Mycobacterium smegmatis against the antimicrobial activity of nitric oxide is provided by mycothiol. Antimicrob Agents Chemother. 2007 Sep;51(9):3364-6. Epub 2007 Jul 16

• « Previous
• 1
• 2
• 3
• Next »